Printed from Voxsanity (voxsanity.com.au) — NCT05484583 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT05484583
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- A diagnosis of small cell lung cancer confirmed by tissue or cell testing.
- Having fewer than 5 areas in the body where the cancer has spread (called "limited spread").
- Having stage IV disease, or a large tumour or lymph nodes that cannot be included in a single radiation treatment plan due to their size or spread across the lungs (confirm with trial site).
- Having received 4 to 6 cycles of Durvalumab combined with standard chemotherapy (platinum + etoposide) before joining, with results showing the cancer either completely responded or partially responded to that treatment.
- A radiation specialist has assessed that the chest and any limited spread areas can be safely treated with radiotherapy.
- Being between 18 and 70 years old at the time of diagnosis.
- Having a general health/activity score of 0 or 1 on the ECOG scale, meaning the person is fully active or has only minor limitations in physical activity.
- Having normal bone marrow function, with blood counts meeting the following minimums: white blood cells ≥ 3 × 10⁹/L, neutrophils ≥ 1.5 × 10⁹/L, haemoglobin ≥ 90 g/L, and platelets ≥ 100 × 10⁹/L.
- Having normal liver and kidney function based on specific blood test results (confirm with trial site for exact values).
- Having a life expectancy of at least 12 weeks.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have received systemic immune-stimulating treatments — such as interferon, interleukin-2, or tumour necrosis factor — within 4 weeks before joining, or within 5 half-lives of that drug, whichever is longer (prior cancer vaccines are allowed).
- People who have used any Chinese herbal medicine to control cancer within 14 days before the first dose.
- People who have needed corticosteroids at a dose higher than prednisone 10 mg/day (or equivalent), or other immune-suppressing drugs, within 14 days before joining — with some exceptions for low-dose, inhaled, or short-course steroids (confirm with trial site).
- People who have received a live vaccine within 4 weeks before joining (standard inactivated flu vaccines are generally allowed; nasal spray flu vaccines, which are live, are not).
- People who have had major surgery requiring general anaesthesia within 28 days before joining.
- People who have previously received an organ transplant or stem cell transplant from another person.
- People with fluid around the heart or in the abdomen that is uncontrolled and requires drainage, or with active, uncontrolled spread of cancer to the lining of the brain, within 2 weeks before joining.
- People with brain metastases that do not meet specific stability criteria — including no signs of progression since completing initial treatment, no ongoing corticosteroid use for brain disease, and only stable doses of anti-seizure medication being used (confirm with trial site for full details).
- People with active autoimmune diseases, or a history of autoimmune disease that could return — with some exceptions for well-controlled conditions such as type 1 diabetes, hypothyroidism, or coeliac disease managed without systemic treatment (confirm with trial site).
- People who have had interstitial lung disease, non-infectious pneumonia, or uncontrolled conditions such as diabetes, high blood pressure, pulmonary fibrosis, or acute lung disease.
- People who have had a severe or ongoing infection requiring systemic antibiotics, antifungal, or antiviral treatment within 2 weeks before joining, including tuberculosis.
- People who have had another active cancer within the 2 years before joining, other than the cancer being studied or certain locally treated, cured cancers such as skin cancers or early-stage cervical or breast cancers (confirm with trial site).
- People with untreated chronic hepatitis B, or a hepatitis B viral load above 500 IU/mL, or active hepatitis C — with specific exceptions for people with stable, treated hepatitis B or cleared hepatitis C (confirm with trial site for full details).
- People with a known history of HIV infection.
- People who have experienced certain serious heart or blood vessel problems, including: heart-related chest pain within 28 days; a blood clot in the lungs within 28 days; a heart attack within 6 months; heart failure rated grade III or IV within 6 months; serious irregular heartbeats within 6 months; a stroke within 6 months; uncontrolled high blood pressure despite medication within 28 days; or fainting or seizures within 28 days.
- People who still have side effects from previous cancer treatment that have not returned to normal or stable levels, except for effects considered low-risk such as hair loss or certain minor nerve or lab changes.
- People with a history of severe allergic reactions to other monoclonal antibody treatments.
- People with underlying medical conditions, abnormal laboratory results, or alcohol or drug dependence that could interfere with the study or make it unsafe to participate.
- People who are currently participating in another treatment-based clinical trial at the same time.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: 13622876524
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Registry
ClinicalTrials.gov
Start date
1 August 2022
Est. completion
1 August 2024
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
overall survival time
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.